Skip to main content

Table 2 Efficacy of dasatinib and nilotinib in patients with CP CML harboring specific mutations

From: P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia

 

CCyR rates, n/N (%)

 

Dasatinib

Nilotinib

Any mutation

158/369 (43)

18/77 (23)

P-loop mutations

61/141 (43)

NR

   L248V

NR

0/2 (0)

   G250E

19/51 (37)

1/4 (25)

   Y253F/H

12/23 (52)

0/8 (0)

   E255K/V

8/24 (33)

0/6 (0)

T315I

0/20 (0)

0/4 (0)

F317L

1/14 (7)

NR*†

F359C/V

14/27 (52)

0/10 (0)*

  1. Dasatinib data are based on 1,093 patients with CP CML enrolled in clinical trials with dasatinib [36]. Nilotinib data are based on 280 patients with CP CML enrolled in a phase 2 clinical trial with nilotinib [42].
  2. *(Adapted from Ref. [45]).
  3. †Considered a nilotinib-sensitive mutation (18 of 45 patients harboring nilotinib-sensitive mutations achieved CCyRs) [45].
  4. CP: chronic phase. CML: chronic myeloid leukemia. CCyR: complete cytogenetic response. NR: not reported.
Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us